Viking Therapeutics, Inc. Stock News
$49.58
7.45%
yesterday
Nasdaq,
Nov 15, 10:17 pm CET
Viking Therapeutics, Inc. Stock News
Negative
Market Watch
●
about 11 hours ago
The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr. his pick to head the Department of Health and Human Services.
Negative
The Motley Fool
●
about 18 hours ago
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Neutral
The Motley Fool
●
3 days ago
Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry.
Neutral
PRNewsWire
●
3 days ago
Results to be Featured in Oral Late Breaker Presentation SAN DIEGO , Nov. 12, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that results from the company's Phase 2b clinical trial of VK2809, the company's novel liver-selectiv...
Negative
The Motley Fool
●
6 days ago
Viking stock has slipped more than 20% from its peak.
Positive
CNBC
●
7 days ago
Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here's how Americans voted on abortion access.
Positive
The Motley Fool
●
8 days ago
All signs are pointing toward its continued success.
Positive
The Motley Fool
●
9 days ago
The company's latest presentation supports the idea that its lead program will make billions.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
